Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Rx Becomes Law Dec. 8; Firms Analyzing Bill, PR Approaches

Executive Summary

The signing of the Medicare prescription drug benefit legislation presents drug companies with the happy challenge of communicating the potential impact of the bill to investors without triggering a political backlash

You may also be interested in...



BIO Top Priority Is Medicare Reimbursement Negotiations, Chairman Says

Negotiating appropriate Medicare reimbursement rates is one of the Biotechnology Industry Organization's top priorities over the next two years, Alkermes CEO and BIO Chairman Richard Pops said Feb. 25

BIO Top Priority Is Medicare Reimbursement Negotiations, Chairman Says

Negotiating appropriate Medicare reimbursement rates is one of the Biotechnology Industry Organization's top priorities over the next two years, Alkermes CEO and BIO Chairman Richard Pops said Feb. 25

Novartis Applauds Medicare Rx Pilot; Overall Bill “Somewhat Negative”

Novartis hopes to see some immediate benefit from the Medicare prescription drug law from a Centers for Medicare & Medicaid Services pilot program to study expanded coverage of oral chemotherapy drugs

Related Content

UsernamePublicRestriction

Register

PS042949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel